The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model

M Bond, G Rogers, J Peters, R Anderson, M Hoyle, A Miners, T Moxham, S Davis, P Thokala, A Wailoo, M Jeffreys, C Hyde
2012 Health Technology Assessment  
Executive summary: Effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of AD
doi:10.3310/hta16210 pmid:22541366 fatcat:jhglpslw2fg23mdxrj3f6cx3be